From: Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study
Respiratory symptom | Total population | Males | Females | |||
---|---|---|---|---|---|---|
OR (95% CI) of phadiatop | OR (95% CI) of phadiatop | OR (95% CI) of phadiatop | ||||
Placebo | Budesonide | Placebo | Budesonide | Placebo | Budesonide | |
Wheezing at any time | 0.99 (0.59–1.67) | 1.18 (0.70–1.99) | 0.88 (0.48–1.60) | 1.26 (0.70–2.26) | 2.06 (0.55–7.78) | 0.51 (0.15–1.71) |
Cough day/night or in a.m. | 0.85 (0.53–1.36) | 1.93 (1.11–3.37)*,$ | 0.87 (0.52–1.45) | 1.94 (1.05–3.57) * | 0.79 (0.26–2.41) | 1.84 (0.47–7.30) |
Phlegm in day/night or in a.m. | 1.21 (0.72–2.03) | 1.67 (0.99–2.82)# | 1.14 (0.65–2.00) | 1.63 (0.93–2.87)# | 1.48 (0.34–6.45) | 1.53 (0.28–8.26) |
Trouble with breathing | 0.84 (0.48–1.47) | 1.76 (0.99–3.11)# | 0.96 (0.50–1.82) | 2.76 (1.45–5.26) *,$ | 0.47 (0.18–1.21) | 0.43 (0.17–1.12)# |
Woken with chest tightness | 2.18 (0.97–4.90)# | 2.32 (0.60–8.91) | 2.17 (0.67–6.99) | 1.33 (0.22–7.85) | 5.76 (1.67–19.86) * | 8.82 (0.63–123.66) |
Attack of dyspnea after activity | 1.01 (0.52–1.95) | 1.11 (0.63–1.96) | 1.04 (0.49–2.20) | 0.87 (0.46–1.64) | 1.03 (0.29–3.63) | 3.67 (0.68–19.70) |